Summary | |
---|---|
Symbol | PRKD2 |
Name | protein kinase D2 |
Aliases | HSPC187; DKFZP586E0820; nPKC-D2; Serine/threonine-protein kinase D2 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm Cell membrane Nucleus Golgi apparatus, trans-Golgi network Note=Translocation to the cell membrane is required for kinase activation. Accumulates in the nucleus upon CK1-mediated phosphorylation after activation of G-protein-coupled receptors. Nuclear accumulation is regulated by blocking nuclear export of active PRKD2 rather than by increasing import. |
Domain |
PF00130 Phorbol esters/diacylglycerol binding domain (C1 domain) PF00069 Protein kinase domain |
Function |
Serine/threonine-protein kinase that converts transient diacylglycerol (DAG) signals into prolonged physiological effects downstream of PKC, and is involved in the regulation of cell proliferation via MAPK1/3 (ERK1/2) signaling, oxidative stress-induced NF-kappa-B activation, inhibition of HDAC7 transcriptional repression, signaling downstream of T-cell antigen receptor (TCR) and cytokine production, and plays a role in Golgi membrane trafficking, angiogenesis, secretory granule release and cell adhesion (PubMed:15604256, PubMed:14743217, PubMed:17077180, PubMed:16928771, PubMed:17962809, PubMed:17951978, PubMed:18262756, PubMed:19192391, PubMed:19001381, PubMed:23503467, PubMed:28428613). May potentiate mitogenesis induced by the neuropeptide bombesin by mediating an increase in the duration of MAPK1/3 (ERK1/2) signaling, which leads to accumulation of immediate-early gene products including FOS that stimulate cell cycle progression (By similarity). In response to oxidative stress, is phosphorylated at Tyr-438 and Tyr-717 by ABL1, which leads to the activation of PRKD2 without increasing its catalytic activity, and mediates activation of NF-kappa-B (PubMed:15604256, PubMed:28428613). In response to the activation of the gastrin receptor CCKBR, is phosphorylated at Ser-244 by CSNK1D and CSNK1E, translocates to the nucleus, phosphorylates HDAC7, leading to nuclear export of HDAC7 and inhibition of HDAC7 transcriptional repression of NR4A1/NUR77 (PubMed:17962809). Upon TCR stimulation, is activated independently of ZAP70, translocates from the cytoplasm to the nucleus and is required for interleukin-2 (IL2) promoter up-regulation (PubMed:17077180). During adaptive immune responses, is required in peripheral T-lymphocytes for the production of the effector cytokines IL2 and IFNG after TCR engagement and for optimal induction of antibody responses to antigens (By similarity). In epithelial cells stimulated with lysophosphatidic acid (LPA), is activated through a PKC-dependent pathway and mediates LPA-stimulated interleukin-8 (IL8) secretion via a NF-kappa-B-dependent pathway (PubMed:16928771). During TCR-induced T-cell activation, interacts with and is activated by the tyrosine kinase LCK, which results in the activation of the NFAT transcription factors (PubMed:19192391). In the trans-Golgi network (TGN), regulates the fission of transport vesicles that are on their way to the plasma membrane and in polarized cells is involved in the transport of proteins from the TGN to the basolateral membrane (PubMed:14743217). Plays an important role in endothelial cell proliferation and migration prior to angiogenesis, partly through modulation of the expression of KDR/VEGFR2 and FGFR1, two key growth factor receptors involved in angiogenesis (PubMed:19001381). In secretory pathway, is required for the release of chromogranin-A (CHGA)-containing secretory granules from the TGN (PubMed:18262756). Downstream of PRKCA, plays important roles in angiotensin-2-induced monocyte adhesion to endothelial cells (PubMed:17951978). Plays a regulatory role in angiogenesis and tumor growth by phosphorylating a downstream mediator CIB1 isoform 2, resulting in vascular endothelial growth factor A (VEGFA) secretion (PubMed:23503467). |
Biological Process |
GO:0001525 angiogenesis GO:0001667 ameboidal-type cell migration GO:0001819 positive regulation of cytokine production GO:0001935 endothelial cell proliferation GO:0001936 regulation of endothelial cell proliferation GO:0001938 positive regulation of endothelial cell proliferation GO:0002250 adaptive immune response GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0003158 endothelium development GO:0003159 morphogenesis of an endothelium GO:0006476 protein deacetylation GO:0008543 fibroblast growth factor receptor signaling pathway GO:0010594 regulation of endothelial cell migration GO:0010595 positive regulation of endothelial cell migration GO:0010631 epithelial cell migration GO:0010632 regulation of epithelial cell migration GO:0010634 positive regulation of epithelial cell migration GO:0016570 histone modification GO:0016575 histone deacetylation GO:0018105 peptidyl-serine phosphorylation GO:0018209 peptidyl-serine modification GO:0030335 positive regulation of cell migration GO:0030947 regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0031056 regulation of histone modification GO:0031058 positive regulation of histone modification GO:0031063 regulation of histone deacetylation GO:0031065 positive regulation of histone deacetylation GO:0032103 positive regulation of response to external stimulus GO:0032623 interleukin-2 production GO:0032637 interleukin-8 production GO:0032663 regulation of interleukin-2 production GO:0032677 regulation of interleukin-8 production GO:0032743 positive regulation of interleukin-2 production GO:0032757 positive regulation of interleukin-8 production GO:0032793 positive regulation of CREB transcription factor activity GO:0033135 regulation of peptidyl-serine phosphorylation GO:0033138 positive regulation of peptidyl-serine phosphorylation GO:0035239 tube morphogenesis GO:0035601 protein deacylation GO:0035767 endothelial cell chemotaxis GO:0035924 cellular response to vascular endothelial growth factor stimulus GO:0038033 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038084 vascular endothelial growth factor signaling pathway GO:0038089 positive regulation of cell migration by vascular endothelial growth factor signaling pathway GO:0040017 positive regulation of locomotion GO:0040036 regulation of fibroblast growth factor receptor signaling pathway GO:0043410 positive regulation of MAPK cascade GO:0043534 blood vessel endothelial cell migration GO:0043535 regulation of blood vessel endothelial cell migration GO:0043536 positive regulation of blood vessel endothelial cell migration GO:0043542 endothelial cell migration GO:0044344 cellular response to fibroblast growth factor stimulus GO:0045743 positive regulation of fibroblast growth factor receptor signaling pathway GO:0045765 regulation of angiogenesis GO:0045766 positive regulation of angiogenesis GO:0045785 positive regulation of cell adhesion GO:0046777 protein autophosphorylation GO:0048010 vascular endothelial growth factor receptor signaling pathway GO:0048514 blood vessel morphogenesis GO:0050673 epithelial cell proliferation GO:0050678 regulation of epithelial cell proliferation GO:0050679 positive regulation of epithelial cell proliferation GO:0050851 antigen receptor-mediated signaling pathway GO:0050852 T cell receptor signaling pathway GO:0050854 regulation of antigen receptor-mediated signaling pathway GO:0050856 regulation of T cell receptor signaling pathway GO:0050857 positive regulation of antigen receptor-mediated signaling pathway GO:0050862 positive regulation of T cell receptor signaling pathway GO:0050920 regulation of chemotaxis GO:0050921 positive regulation of chemotaxis GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051092 positive regulation of NF-kappaB transcription factor activity GO:0051272 positive regulation of cellular component movement GO:0060326 cell chemotaxis GO:0060562 epithelial tube morphogenesis GO:0061154 endothelial tube morphogenesis GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0070374 positive regulation of ERK1 and ERK2 cascade GO:0071774 response to fibroblast growth factor GO:0071897 DNA biosynthetic process GO:0089700 protein kinase D signaling GO:0090045 positive regulation of deacetylase activity GO:0090130 tissue migration GO:0090132 epithelium migration GO:0090287 regulation of cellular response to growth factor stimulus GO:0090311 regulation of protein deacetylation GO:0090312 positive regulation of protein deacetylation GO:0098732 macromolecule deacylation GO:1901342 regulation of vasculature development GO:1901725 regulation of histone deacetylase activity GO:1901727 positive regulation of histone deacetylase activity GO:1902275 regulation of chromatin organization GO:1904018 positive regulation of vasculature development GO:1905269 positive regulation of chromatin organization GO:2000147 positive regulation of cell motility GO:2000278 regulation of DNA biosynthetic process GO:2000573 positive regulation of DNA biosynthetic process GO:2001026 regulation of endothelial cell chemotaxis GO:2001028 positive regulation of endothelial cell chemotaxis |
Molecular Function |
GO:0004674 protein serine/threonine kinase activity GO:0004697 protein kinase C activity |
Cellular Component | - |
KEGG |
hsa04015 Rap1 signaling pathway |
Reactome |
R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-1660661: Sphingolipid de novo biosynthesis R-HSA-428157: Sphingolipid metabolism |
Summary | |
---|---|
Symbol | PRKD2 |
Name | protein kinase D2 |
Aliases | HSPC187; DKFZP586E0820; nPKC-D2; Serine/threonine-protein kinase D2 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between PRKD2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | PRKD2 |
Name | protein kinase D2 |
Aliases | HSPC187; DKFZP586E0820; nPKC-D2; Serine/threonine-protein kinase D2 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of PRKD2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | PRKD2 |
Name | protein kinase D2 |
Aliases | HSPC187; DKFZP586E0820; nPKC-D2; Serine/threonine-protein kinase D2 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of PRKD2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of PRKD2 in various data sets.
|
Summary | |
---|---|
Symbol | PRKD2 |
Name | protein kinase D2 |
Aliases | HSPC187; DKFZP586E0820; nPKC-D2; Serine/threonine-protein kinase D2 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRKD2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | PRKD2 |
Name | protein kinase D2 |
Aliases | HSPC187; DKFZP586E0820; nPKC-D2; Serine/threonine-protein kinase D2 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRKD2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRKD2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | PRKD2 |
Name | protein kinase D2 |
Aliases | HSPC187; DKFZP586E0820; nPKC-D2; Serine/threonine-protein kinase D2 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRKD2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | PRKD2 |
Name | protein kinase D2 |
Aliases | HSPC187; DKFZP586E0820; nPKC-D2; Serine/threonine-protein kinase D2 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of PRKD2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | PRKD2 |
Name | protein kinase D2 |
Aliases | HSPC187; DKFZP586E0820; nPKC-D2; Serine/threonine-protein kinase D2 |
Chromosomal Location | 19q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between PRKD2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |